Bryan Jones PhD

Sollis TherapeuticsBryan Jones PhD

Co-Founder and Chief Operating Officer

Dr. Jones is a Co-Founder is the Chief Operating Officer of Sollis Therapeutics. He has more than 25 years of experience with Biotech and Specialty Pharmaceutical companies with specific expertise in Business and Product development. Prior to Sollis, he was the Vice President of Operations at Sorrento Therapeutics where he led the development of resiniferatoxin, a neuraxially administered therapy to ablate afferent nerves for treatment of chronic pain and neurogenic inflammation. While there, he also filed the ANDA in canines for bone pain associated with cancer and led the creation of its subsidiary, ARK Animal Health.

Previously he was Chief Operating Officer of two startup companies: Sherrington and Mt. Cook as well as Senior Director of Business Development at Amylin, and Vice President of Business Development at Kemia. Earlier in his career, he worked in research at Bristol-Myers Squibb and on products such as Cialis® with ICOS.

Dr. Jones received his B.S. from Iowa State University and holds a Ph.D. in genetics from the University of Washington.